NCT02979548 - Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

December 31, 2018

Conditions

Chemotherapy Induced VomitingAcute Myeloid Leukemia

Interventions

DRUG

Aprepitant

Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.

DRUG

Ondansetron

Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting

DRUG

Metoclopramide

Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.

Trial Locations (1)

110029

RECRUITING

Irch, Aiims , New Delhi , India, New Delhi